This pathway shows the role of microRNAs in the process of cardiac hypertrophy. Converted from the humane pathway. MicroRNA targets were predicted by the TargetScan algorithm, and the predicted interactions are shown in red, dashed lines. MicroRNAs are shown as purple rounded rectangles. It is not sure which WNT and frizzled proteins influence cardiac hypertrophy. Though there are strong indications that WNT3A, WNT5A, frizzled1 and frizzled2 play a role in cardiac hypertrophy. Thus these have been added to the pathway instead of all the WNT and frizzled proteins. Experiments which will shed light on this are still being done. This pathway was inferred from Homo sapiens pathway [http://www.wikipathways.org/index.php?title=Pathway:WP1544&oldid=37553 WP1544(r37553)] with a 96% conversion rate. e83 e83 e83 e83 b12 e83 df3 df3 fbe f1f f1f f1f df3 df3 f1f df3 dd8 df3 ec6 hypertrophic cardimyopathy pathway PW:0000296 Pathway Ontology 16936699 PubMed Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006 Heineke J Molkentin JD 10698680 PubMed The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000 Vanhaesebroeck B Alessi DR 10086361 PubMed Calcineurin and human heart failure. Nat Med 1999 Lim HW Molkentin JD 18342376 PubMed The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci 2008 Blankesteijn WM van de Schans VA ter Horst P Smits JF 19018142 PubMed MicroRNA: novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology 2009 Wang J Xu R Lin F Zhang S Zhang G Hu S Zheng Z 20407820 PubMed STAT3 and cardiac remodeling. Heart Fail Rev 2010 Haghikia A Stapel B Hoch M Hilfiker-Kleiner D 17468766 PubMed MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007 Carè A Catalucci D Felicetti F Bonci D Addario A Gallo P Bang ML Segnalini P Gu Y Dalton ND Elia L Latronico MV Høydal M Autore C Russo MA Dorn GW 2nd Ellingsen O Ruiz-Lozano P Peterson KL Croce CM Peschle C Condorelli G